The metabolic syndrome and type 2 diabetes are associated with myocardial dysfunction
Problems
Pathophysiology of diastolic dysfunction
Diagnostics
Clinical trials
First author [reference no.] | No. of individuals (age [years]) | HbA1c (%) | Patients’ diabetes and cardiac specifications | Intervention | Study duration (months) | Metabolic and clinical findings | Effect on diastolic function (imaging technique) |
---|---|---|---|---|---|---|---|
von Bibra [53] | 25 (60) | 7.2 | T2D, no HF | Increase in insulin vs metformin | 0.7 | Fasting glucose reduced by 3.7 mmol/l in both groups | E′ improved (from 7.5 to 8.6 cm/s) in insulin group (pTDI) |
Grandi [55] | 36 (36) | 10.1 | T1D, no CAD, BMI <25 kg/m2, normotensive | Increase in insulin | 12 | HbA1c reduced to 8.1%, fasting glucose by 1.0 mmol/l | Peak LV diameter lengthening rate improved (from 4.4 to 5.2 s−1) (digitised M-mode echo) |
von Bibra [59] | 83 (62) | 6.6 | T2D, no HF | Increase in insulin | 0.7 and 12 | Fasting glucose reduced by 1.5 mmol/l | E′ improved (from 7.6 to 8.3 cm/s) (pTDI) |
Jarnert [90] | 39 (60) | 6.0 and 5.9 | T2D, no insulin, no CAD or HF, ultrasonographic signs of diastolic dysfunction | Increase in insulin vs OAD | 4 | HbA1c reduced to 5.2%, fasting glucose by 1.0 mmol/l in both groups | E′ unchanged in both groups (10.3 cm/s) (pTDI) |
von Bibra [56] | 61 (64) | 6.4 | T2D, no HF, well controlled on CT vs ICT for 24 months, HbA1c and fasting glucose comparable | Pure carbohydrate (48 g) test meal | 2 h | Δ glucose 3.3 with CT vs 1.0 mmol/l with ICT | E′ worse in CT (6.8 cm/s) vs ICT (7.7 cm/s) (pTDI) |
Brassard [94] | 23 (57) | 6.2 | Sedentary T2D on diet or OAD, well controlled, no CAD | Aerobic exercise programme vs no exercise | 3 | M⩒O2 increased (from 28.6 to 32.7 ml kg−1 min−1) with exercise | Improvement in diastolic dysfunction with exercise (echo-Doppler) |
Hordern [95] | 176 (56) | 7.5 | T2D, no CAD, no HF | Moderate/vigorous (gym) exercise vs no gym | 12 | Improved 6-min walk test, heart rate in both groups but BMI, HDL, blood pressure, ⩒O2 with exercise | Improvement of E′ by 0.5 cm/s, systolic velocity by 0.7 cm/s in both groups (colour tissue Doppler imaging) |
Hammer [96] | 12 (48) | 7.9 | T2D, on insulin, C-peptide >0.8 ng/l, BMI 36 kg/m2, no CAD | Very-low-energy diet (450 kcal [1882 kJ]/day) and insulin discontinued | 4 | BMI reduced to 28 kg/m2, HbA1c to 6.7%, fasting glucose from 11.4 to 6.7 mmol/l, TG from 2.1 to 1.1 mmol/l | Decrease in myocardial TG content (from 0.88% to 0.64%) and left ventricular mass (from 118 to 99 g), increase in E/A (CMR) |
von Bibra [47] | 15 (59) | 6.8 | T2D, metformin-treated, no CAD or HF | Rosiglitazone (8 mg) vs glimepiride (3 mg) | 4 | Fasting glucose reduced by 1.0 and postmeal glucose by 2.0 mmol/l by rosiglitazone | E′ improved (from 7.9 to 8.9 cm/s) by rosiglitazone with a significant association with malondialdehyde reduction (pTDI) |
van der Meer [99] | 78 (56) | 7.0 | Uncomplicated T2D, no use of insulin, no CAD | Pioglitazone (30 mg) vs metformin (2 g) | 6 | Fasting glucose reduced by 0.8 mmol/l by pioglitazone | Filling rate improved by pioglitazone vs metformin (CMR) |
Siegmund [100] | 16 (5) | 6.5 | T2D on ICT, no CAD, no or mild hypertension | Ramipril (10 mg) vs no ramipril | 9 | Glycaemic control and blood pressure unchanged in both groups | E′ improved (from 7.8 to 8.6 cm/s) by ramipril (pTDI) |
Okura [65] | 430 (67) | – | CAD, no HF or MI; diabetes in 30% of individuals | Statin vs no statin | 22 | Cardiac death or HF 2.3% in statin vs 15.4% in no statin group | LV filling pressure (E/E′) and no statin are multivariate predictors of death and HF (pTDI) |